Literature DB >> 1454338

Serious complications of topical mitomycin-C after pterygium surgery.

R S Rubinfeld1, R R Pfister, R M Stein, C S Foster, N F Martin, S Stoleru, A R Talley, M G Speaker.   

Abstract

BACKGROUND: The use of topical mitomycin (mitomycin-C) as a medical adjunct to pterygium and glaucoma surgery is increasing.
METHODS: The authors report on a series of 10 patients who experienced serious, vision-threatening complications associated with the use of this drug after pterygium surgery.
RESULTS: Complications included severe secondary glaucoma (4 patients), corneal edema (3 patients), corneal perforation (1 patient), corectopia (2 patients), iritis (8 patients), sudden onset mature cataract (2 patients), scleral calcification (1 patient) and incapacitating photophobia and pain (8 patients). Two patients required penetrating keratoplasties and a third required three lamellar keratoplasties. Another patient underwent four additional surgeries including a conjunctival Z-plasty, scleral patch grafting, and conjunctival autografting before his intractable pain and photophobia resolved 15 months after the original surgery. Because of these complications, 6 patients required a total of 20 return visits to the operating room after their original pterygium surgery. In 5 eyes, visual acuity remained at 20/200 or less. Three of the six patients with the most severe complications had concomitant chronic external diseases (rosacea [3 patients], ichthyosis [1 patient], keratitis sicca [1 patient]).
CONCLUSION: The authors urge extreme caution in the use of mitomycin. If mitomycin is used, the lowest possible concentration should be applied for the shortest time period in an effort to avoid these complications. A prospective multicenter study of the ophthalmic use of this medication is needed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1454338     DOI: 10.1016/s0161-6420(92)31749-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  111 in total

1.  Analysis of variation in success rates in conjunctival autografting for primary and recurrent pterygium.

Authors:  S E Ti; S P Chee; K B Dear; D T Tan
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

2.  Serious corneoscleral complications after pterygium excision with mitomycin C.

Authors:  B Safianik; I Ben-Zion; H J Garzozi
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

3.  Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery.

Authors:  S Amano; Y Motoyama; T Oshika; S Eguchi; K Eguchi
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

4.  Mitomycin C dissolved in a reversible thermosetting gel: target tissue concentrations in the rabbit eye.

Authors:  K Ichien; T Yamamoto; Y Kitazawa; A Oguri; H Ando; Y Kondo
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

5.  New approach for pterygium removal using 20 % ethanol.

Authors:  Erez Tsumi; Jaime Levy; Anry Pitchkhadze; Amjad Baidousi; Tova Lifshitz
Journal:  Int Ophthalmol       Date:  2012-06-21       Impact factor: 2.031

Review 6.  [Operative techniques for surgical treatment of primary and recurrent pterygia].

Authors:  W Sekundo; K Droutsas; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

7.  [Pterygium. Etiology, clinical aspects and novel adjuvant therapies].

Authors:  L M Heindl; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

8.  Epiphora as a side effect of topical mitomycin C.

Authors:  E Dafgård Kopp; S Seregard
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

9.  Mitomycin C for pterygium: long term evaluation.

Authors:  F Raiskup; A Solomon; D Landau; M Ilsar; J Frucht-Pery
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

10.  Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.

Authors:  P T Finger; G Czechonska; S Liarikos
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.